Trial Profile
A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute CABG, Valve Replacement or a Combination Thereof
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms CABG-01
- Sponsors Pharmacosmos
- 13 Jun 2014 New trial record